Cytosorbents Stock Price, News & Analysis (NASDAQ:CTSO)

$7.85 +0.03 (+0.38 %)
(As of 02/23/2018 01:06 PM ET)
Previous Close$7.85
Today's Range$7.80 - $8.10
52-Week Range$3.30 - $8.10
Volume378,600 shs
Average Volume174,104 shs
Market Capitalization$226.66 million
P/E Ratio-20.79
Dividend YieldN/A
Beta-0.18

About Cytosorbents (NASDAQ:CTSO)

Cytosorbents logoCytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Receive CTSO News and Ratings via Email

Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CTSO
CUSIPN/A
Phone+1-973-3298885

Debt

Debt-to-Equity Ratio0.73%
Current Ratio3.36%
Quick Ratio3.17%

Price-To-Earnings

Trailing P/E Ratio-20.7894736842105
Forward P/E Ratio-30.19
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.53 million
Price / Sales23.63
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-392.50

Profitability

Trailing EPS($0.38)
Net Income$-11,930,000.00
Net Margins-67.83%
Return on Equity-233.72%
Return on Assets-57.58%

Miscellaneous

Employees65
Outstanding Shares28,690,000

Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

How were Cytosorbents' earnings last quarter?

Cytosorbents Corp (NASDAQ:CTSO) issued its quarterly earnings data on Tuesday, August, 9th. The medical research company reported ($0.12) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.03. The medical research company had revenue of $1.90 million for the quarter, compared to analysts' expectations of $2.18 million. Cytosorbents had a negative return on equity of 233.72% and a negative net margin of 67.83%. View Cytosorbents' Earnings History.

When will Cytosorbents make its next earnings announcement?

Cytosorbents is scheduled to release their next quarterly earnings announcement on Friday, March, 2nd 2018. View Earnings Estimates for Cytosorbents.

Where is Cytosorbents' stock going? Where will Cytosorbents' stock price be in 2018?

5 brokers have issued 12-month price objectives for Cytosorbents' shares. Their forecasts range from $7.00 to $14.00. On average, they expect Cytosorbents' stock price to reach $10.65 in the next year. View Analyst Ratings for Cytosorbents.

What are Wall Street analysts saying about Cytosorbents stock?

Here are some recent quotes from research analysts about Cytosorbents stock:

  • 1. Maxim Group analysts commented, "CytoSorbents reported 3Q17 with revenue of $3.8M ($3.4M in product sales and $375K in grant income) and spent $5.9M in the quarter for a net loss of $2M. CytoSorb sales continue to rise with 11% sequential growth (61% YoY). The increase in product revenue was driven by an increase in direct sales to both new customers and repeat orders from existing customers, as well as increased sales to distributers. The company did not provide guidance, but reiterated it expects 2H17 sales to exceed 1H17. CytoSorbents ended the period with $15.4M in cash." (11/10/2017)
  • 2. HC Wainwright analysts commented, "CytoSorbents reported full-year 2016 financial results and held a conference call on March 3. The company reported revenues of $9.5M, higher than our estimate of $8.7M, and a net loss of $0.47 per share, compared to our estimated net loss of $0.40 per share. The differences mainly resulted from higher-than-expected product sales, offset by increased R&D and SG&A increases. We have updated our model to reflect the 2016 financial results." (3/6/2017)

Who are some of Cytosorbents' key competitors?

Who are Cytosorbents' key executives?

Cytosorbents' management team includes the folowing people:

  • Al Kraus, Chairman of the Board (Age 70)
  • Phillip P. Chan M.D., Ph.D., President, Chief Executive Officer, Director (Age 45)
  • Kathleen P. Bloch CPA, Chief Financial Officer (Age 58)
  • Vincent J. Capponi, Chief Operating Officer (Age 55)
  • Eric G. Mortensen, Chief Medical Officer
  • Michael G. Bator, Director
  • James T. Gunton, Independent Director (Age 49)
  • Edward R. Jones M.D., Independent Director (Age 66)
  • Alan D. Sobel, Independent Director (Age 54)

Who owns Cytosorbents stock?

Cytosorbents' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Skylands Capital LLC (2.53%), Millennium Management LLC (0.57%), B. Riley Financial Inc. (0.53%), Raymond James & Associates (0.35%), PEAK6 Investments L.P. (0.35%) and BlueCrest Capital Management Ltd (0.21%). Company insiders that own Cytosorbents stock include Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents.

Who bought Cytosorbents stock? Who is buying Cytosorbents stock?

Cytosorbents' stock was acquired by a variety of institutional investors in the last quarter, including Skylands Capital LLC, B. Riley Financial Inc., Millennium Management LLC, BlueCrest Capital Management Ltd, Raymond James & Associates, Goldman Sachs Group Inc., Fortaleza Asset Management Inc. and Wells Fargo & Company MN. Company insiders that have bought Cytosorbents stock in the last two years include Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Insider Buying and Selling for Cytosorbents.

How do I buy Cytosorbents stock?

Shares of Cytosorbents can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytosorbents' stock price today?

One share of Cytosorbents stock can currently be purchased for approximately $7.85.

How big of a company is Cytosorbents?

Cytosorbents has a market capitalization of $226.66 million and generates $9.53 million in revenue each year. The medical research company earns $-11,930,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Cytosorbents employs 65 workers across the globe.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 Deerpark Dr Ste K, MONMOUTH JUNCTION, NJ 08852-1921, United States. The medical research company can be reached via phone at +1-973-3298885 or via email at [email protected]


MarketBeat Community Rating for Cytosorbents (CTSO)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  333
MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cytosorbents (NASDAQ:CTSO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.65$10.60$10.45$12.71
Price Target Upside: 37.95% upside41.33% upside60.77% upside176.27% upside

Cytosorbents (NASDAQ:CTSO) Consensus Price Target History

Price Target History for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2018B. RileyReiterated RatingBuy$11.25LowView Rating Details
1/9/2018HC WainwrightReiterated RatingBuy$14.00MediumView Rating Details
1/8/2018Maxim GroupSet Price TargetBuy$12.00N/AView Rating Details
7/25/2017AegisReiterated RatingBuy$9.00HighView Rating Details
6/7/2017CowenInitiated CoverageOutperform$7.00HighView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$24.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Cytosorbents (NASDAQ:CTSO) Earnings History and Estimates Chart

Earnings by Quarter for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ CTSO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018N/AView Earnings Details
11/9/2017Q3 2017($0.07)($0.07)$3.67 million$3.45 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.06)($0.04)$3.29 million$3.57 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.11)($0.05)$2.99 million$3.11 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.10)($0.16)$2.59 million$3.08 millionViewN/AView Earnings Details
11/7/2016Q3($0.11)($0.11)$2.35 million$2.14 millionViewListenView Earnings Details
8/9/2016Q216($0.09)($0.12)$2.18 million$1.90 millionViewN/AView Earnings Details
5/9/2016Q116($0.10)($0.08)$1.73 million$1.80 millionViewN/AView Earnings Details
3/9/2016Q415($0.08)($0.08)$1.51 million$1.76 millionViewN/AView Earnings Details
11/13/2015Q315($0.10)($0.11)$1.26 million$1.30 millionViewListenView Earnings Details
8/13/2015Q215($0.11)$0.05$0.92 million$0.96 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.11)$0.80 million$0.72 millionViewListenView Earnings Details
11/12/2014Q3 2014($0.25)($0.25)$1.28 million$1.16 millionViewN/AView Earnings Details
8/12/2014Q2 2014($0.01)($0.01)$1.13 million$1.03 millionViewN/AView Earnings Details
5/14/2014Q1 2014($0.25)($0.25)$1.02 million$1.06 millionViewN/AView Earnings Details
3/31/2014Q4 2013($0.01)($0.01)$8.34 million$0.88 millionViewN/AView Earnings Details
11/6/2013Q3 2013($0.25)($0.25)$0.70 million$0.88 millionViewN/AView Earnings Details
8/14/2013Q2 2013($0.25)($0.25)$0.29 millionViewN/AView Earnings Details
5/16/2013Q1 2013($0.25)$0.85 million$0.37 millionViewN/AView Earnings Details
4/3/2013Q4 2012($0.25)ViewN/AView Earnings Details
11/21/2012Q3 2012($0.25)($0.25)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cytosorbents (NASDAQ:CTSO) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.10)($0.10)($0.10)
Q2 20181($0.11)($0.11)($0.11)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Cytosorbents (NASDAQ:CTSO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cytosorbents (NASDAQ CTSO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 9.96%
Insider Trades by Quarter for Cytosorbents (NASDAQ:CTSO)
Institutional Ownership by Quarter for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ CTSO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/12/2018Kathleen P BlochCFOSell12,400$7.75$96,100.00241,038View SEC Filing  
1/8/2018Kathleen P BlochCFOSell32,400$7.30$236,520.00248,638View SEC Filing  
11/27/2017Vincent CapponiCOOSell4,000$7.00$28,000.00271,062View SEC Filing  
6/9/2017Eric R MortensenInsiderBuy2,500$4.04$10,100.002,500View SEC Filing  
6/9/2017Michael G. BatorDirectorBuy1,500$4.12$6,180.00View SEC Filing  
6/8/2017Phillip P. ChanInsiderBuy3,700$4.00$14,800.00View SEC Filing  
6/8/2017Vincent CapponiCOOBuy2,500$4.00$10,000.00View SEC Filing  
6/5/2017Phillip P. ChanInsiderBuy6,300$4.00$25,200.00View SEC Filing  
5/15/2017Kathleen P. BlochCFOBuy1,000$4.34$4,340.00View SEC Filing  
12/9/2016Phillip P. ChanInsiderBuy4,600$5.40$24,840.00View SEC Filing  
12/6/2016Kathleen P BlochCFOBuy1,000$4.83$4,830.00122,325View SEC Filing  
8/24/2016Phillip P ChanInsiderBuy5,000$4.89$24,450.00121,648View SEC Filing  
6/7/2016Michael G BatorDirectorBuy3,000$4.88$14,640.003,000View SEC Filing  
10/29/2015Vincent CapponiCOOSell4,000$7.50$30,000.0016,724View SEC Filing  
10/15/2015Al KrausDirectorSell6,774$6.22$42,134.2855,746View SEC Filing  
10/8/2015Al KrausDirectorSell10,000$6.39$63,900.0055,746View SEC Filing  
10/1/2015Al KrausDirectorSell10,000$6.26$62,600.0055,746View SEC Filing  
9/24/2015Al KrausDirectorSell10,000$6.44$64,400.0055,746View SEC Filing  
9/17/2015Al KrausDirectorSell10,000$6.64$66,400.0055,746View SEC Filing  
9/10/2015Al KrausDirectorSell10,000$7.26$72,600.0055,746View SEC Filing  
9/3/2015Al KrausDirectorSell10,000$7.26$72,600.0055,746View SEC Filing  
8/27/2015Al KrausDirectorSell10,000$6.39$63,900.0055,746View SEC Filing  
8/20/2015Al KrausDirectorSell10,000$7.26$72,600.0055,746View SEC Filing  
8/13/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  
7/23/2015Al KrausDirectorSell10,000$6.28$62,800.00View SEC Filing  
7/16/2015Al KrausDirectorSell10,000$6.33$63,300.00View SEC Filing  
7/9/2015Al KrausDirectorSell10,000$5.98$59,800.00View SEC Filing  
7/2/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/25/2015Al KrausDirectorSell13,205$7.33$96,792.65View SEC Filing  
6/18/2015Al KrausDirectorSell10,000$5.78$57,800.00View SEC Filing  
6/11/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/4/2015Al KrausDirectorSell10,000$6.30$63,000.00View SEC Filing  
5/28/2015Al KrausDirectorSell10,000$6.32$63,200.00View SEC Filing  
11/17/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/10/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/3/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
10/27/2014Al KrausDirectorSell100,000$0.24$24,000.00View SEC Filing  
10/10/2014James T GuntonDirectorSell1,240,762$0.24$297,782.88View SEC Filing  
10/6/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/29/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/25/2014Al KrausDirectorSell41,500$0.23$9,545.00View SEC Filing  
9/22/2014Al KrausDirectorSell8,500$0.23$1,955.00View SEC Filing  
9/15/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/12/2014James T GuntonDirectorSell30,450$0.24$7,308.00View SEC Filing  
9/8/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/5/2014James T GuntonDirectorSell100,000$0.24$24,000.00View SEC Filing  
9/2/2014Al KrausDirectorSell50,000$0.25$12,500.00View SEC Filing  
9/2/2014Kathleen P BlochCFOBuy65,000$0.23$14,950.00View SEC Filing  
8/28/2014James T GuntonDirectorSell214,387$0.24$51,452.88View SEC Filing  
8/27/2014James T GuntonDirectorSell1,360,000$0.24$326,400.00View SEC Filing  
8/25/2014Al KrausDirectorSell100,000$0.25$25,000.00View SEC Filing  
8/18/2014Al KrausDirectorSell100,000$0.27$27,000.00View SEC Filing  
8/11/2014Al KrausDirectorSell100,000$0.28$28,000.00View SEC Filing  
8/4/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/21/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/10/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/7/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
6/23/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
6/18/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
5/20/2014Kathleen P BlochCFOBuy110,000$0.24$26,400.00View SEC Filing  
9/4/2012Phillip P ChanCEOBuy190,000$0.13$24,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cytosorbents (NASDAQ CTSO) News Headlines

Source:
DateHeadline
$4.57 Million in Sales Expected for Cytosorbents Corp (CTSO) This Quarter$4.57 Million in Sales Expected for Cytosorbents Corp (CTSO) This Quarter
www.americanbankingnews.com - February 17 at 2:28 AM
Zacks: Brokerages Expect Cytosorbents Corp (CTSO) Will Post Earnings of -$0.10 Per ShareZacks: Brokerages Expect Cytosorbents Corp (CTSO) Will Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - February 15 at 9:12 PM
CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia - PR Newswire (press release)CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia - PR Newswire (press release)
www.prnewswire.com - February 15 at 8:13 AM
CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in MalaysiaCytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia
finance.yahoo.com - February 15 at 8:13 AM
Cytosorbents Corp (CTSO) Given Average Recommendation of "Buy" by BrokeragesCytosorbents Corp (CTSO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 14 at 1:28 AM
Cytosorbents (CTSO) vs. Nanosphere (NSPH) Financial AnalysisCytosorbents (CTSO) vs. Nanosphere (NSPH) Financial Analysis
www.americanbankingnews.com - February 11 at 1:18 PM
Analyzing Pacific Biosciences of California (PACB) and Cytosorbents (CTSO)Analyzing Pacific Biosciences of California (PACB) and Cytosorbents (CTSO)
www.americanbankingnews.com - February 8 at 7:02 PM
CytoSorbents to Present at the 20th Annual BIO CEO & Investor ConferenceCytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 9:32 AM
New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative ... - PR Newswire (press release)New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative ... - PR Newswire (press release)
www.prnewswire.com - February 3 at 4:05 PM
New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood PurificationNew Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification
finance.yahoo.com - February 1 at 9:39 AM
-$0.10 Earnings Per Share Expected for Cytosorbents Corp (CTSO) This Quarter-$0.10 Earnings Per Share Expected for Cytosorbents Corp (CTSO) This Quarter
www.americanbankingnews.com - January 29 at 9:14 PM
Cytosorbents (CTSO) Buy Rating Reiterated at B. RileyCytosorbents' (CTSO) Buy Rating Reiterated at B. Riley
www.americanbankingnews.com - January 25 at 1:58 PM
Cytosorbents Corp (CTSO) Receives Average Rating of "Buy" from AnalystsCytosorbents Corp (CTSO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 20 at 1:28 AM
Cytosorbents Corp (CTSO) CFO Kathleen P. Bloch Sells 12,400 SharesCytosorbents Corp (CTSO) CFO Kathleen P. Bloch Sells 12,400 Shares
www.americanbankingnews.com - January 17 at 9:32 PM
CTSO: Q4 Preannouncement, Our Initial Thoughts on REFRESH IICTSO: Q4 Preannouncement, Our Initial Thoughts on REFRESH II
finance.yahoo.com - January 12 at 4:59 PM
Kathleen P. Bloch Sells 32,400 Shares of Cytosorbents Corp (CTSO) StockKathleen P. Bloch Sells 32,400 Shares of Cytosorbents Corp (CTSO) Stock
www.americanbankingnews.com - January 11 at 12:34 AM
Cytosorbents (CTSO) Given a $12.00 Price Target by Maxim Group AnalystsCytosorbents (CTSO) Given a $12.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - January 8 at 6:08 PM
CytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter - PR Newswire (press release)CytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter - PR Newswire (press release)
www.prnewswire.com - January 8 at 9:40 AM
CytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder LetterCytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter
finance.yahoo.com - January 8 at 9:40 AM
CytoSorbents To Provide Corporate Update at Biotech Showcase ... - PR Newswire (press release)CytoSorbents To Provide Corporate Update at Biotech Showcase ... - PR Newswire (press release)
www.prnewswire.com - January 3 at 5:13 PM
CytoSorbents To Provide Corporate Update at Biotech Showcase 2018CytoSorbents To Provide Corporate Update at Biotech Showcase 2018
finance.yahoo.com - January 3 at 8:51 AM
CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 9:38 AM
$4.12 Million in Sales Expected for Cytosorbents Corp (CTSO) This Quarter$4.12 Million in Sales Expected for Cytosorbents Corp (CTSO) This Quarter
www.americanbankingnews.com - December 29 at 6:52 PM
Streetwise Reports Examines an Immunotherapy Firm That Received a Green Light from FDA for Pivotal TrialStreetwise Reports Examines an Immunotherapy Firm That Received a Green Light from FDA for Pivotal Trial
finance.yahoo.com - December 28 at 3:48 PM
-$0.10 EPS Expected for Cytosorbents Corp (CTSO) This Quarter-$0.10 EPS Expected for Cytosorbents Corp (CTSO) This Quarter
www.americanbankingnews.com - December 27 at 12:33 PM
Head to Head Comparison: IRIDEX (IRIX) and Cytosorbents (CTSO)Head to Head Comparison: IRIDEX (IRIX) and Cytosorbents (CTSO)
www.americanbankingnews.com - December 26 at 4:08 PM
Cytosorbents Corp (CTSO) Given Consensus Rating of "Buy" by BrokeragesCytosorbents Corp (CTSO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 26 at 1:38 AM
Cytosorbents (CTSO) Announces FDA Approval of U.S. REFRESH 2 ... - StreetInsider.comCytosorbents (CTSO) Announces FDA Approval of U.S. REFRESH 2 ... - StreetInsider.com
www.streetinsider.com - December 23 at 2:05 AM
Cytosorbents (CTSO) Announces FDA Approval of U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application with ConditionsCytosorbents (CTSO) Announces FDA Approval of U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application with Conditions
www.streetinsider.com - December 22 at 9:47 AM
B. Riley Analysts Give Cytosorbents (CTSO) a $11.00 Price TargetB. Riley Analysts Give Cytosorbents (CTSO) a $11.00 Price Target
www.americanbankingnews.com - December 22 at 7:18 AM
Cytosorbents (CTSO) Given a $12.00 Price Target at Maxim GroupCytosorbents (CTSO) Given a $12.00 Price Target at Maxim Group
www.americanbankingnews.com - December 21 at 7:16 PM
CytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE ApplicationCytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application
finance.yahoo.com - December 21 at 5:11 PM
CTSO: Large Infective Endocarditis Clinical Study Could Be Win-Win for CytoSorbentsCTSO: Large Infective Endocarditis Clinical Study Could Be Win-Win for CytoSorbents
finance.yahoo.com - December 19 at 5:08 PM
CytoSorbents Receives $676739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate ... - PR Newswire (press release)CytoSorbents Receives $676739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate ... - PR Newswire (press release)
www.prnewswire.com - December 19 at 9:42 AM
CytoSorbents Receives $676,739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer ProgramCytoSorbents Receives $676,739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
finance.yahoo.com - December 19 at 9:42 AM
ValuEngine Lowers Cytosorbents (CTSO) to SellValuEngine Lowers Cytosorbents (CTSO) to Sell
www.americanbankingnews.com - December 16 at 4:22 PM
Cytosorbents (CTSO) PT Set at $12.00 by Maxim GroupCytosorbents (CTSO) PT Set at $12.00 by Maxim Group
www.americanbankingnews.com - December 11 at 5:08 PM
German Federal Ministry of Education and Research to Fund the CytoSorb® Endocarditis REMOVE TrialGerman Federal Ministry of Education and Research to Fund the CytoSorb® Endocarditis REMOVE Trial
finance.yahoo.com - December 11 at 10:24 AM
 Analysts Anticipate Cytosorbents Corp (CTSO) Will Post Quarterly Sales of $4.23 Million Analysts Anticipate Cytosorbents Corp (CTSO) Will Post Quarterly Sales of $4.23 Million
www.americanbankingnews.com - December 11 at 4:04 AM
Insider Selling: Cytosorbents Corp (CTSO) COO Sells 4,000 Shares of StockInsider Selling: Cytosorbents Corp (CTSO) COO Sells 4,000 Shares of Stock
www.americanbankingnews.com - December 8 at 6:22 PM
ETFs with exposure to CytoSorbents Corp. : December 8, 2017ETFs with exposure to CytoSorbents Corp. : December 8, 2017
finance.yahoo.com - December 8 at 5:03 PM
Cytosorbents Corp (CTSO) Receives Consensus Rating of "Buy" from AnalystsCytosorbents Corp (CTSO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 1 at 4:57 AM
Is Cytosorbents Corporation’s (CTSO) Balance Sheet Strong Enough To Weather A Storm?Is Cytosorbents Corporation’s (CTSO) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 24 at 11:00 AM
FY2018 EPS Estimates for Cytosorbents Corporation (CTSO) Cut by AnalystFY2018 EPS Estimates for Cytosorbents Corporation (CTSO) Cut by Analyst
www.americanbankingnews.com - November 23 at 4:30 PM
$4.25 Million in Sales Expected for Cytosorbents Corporation (CTSO) This Quarter$4.25 Million in Sales Expected for Cytosorbents Corporation (CTSO) This Quarter
www.americanbankingnews.com - November 23 at 6:32 AM
CTSO: Germany Reimbursement Rebounds, Drives Strong Record ProductCTSO: Germany Reimbursement Rebounds, Drives Strong Record Product
finance.yahoo.com - November 21 at 5:48 PM
HC Wainwright Reaffirms "Buy" Rating for Cytosorbents Corporation (CTSO)HC Wainwright Reaffirms "Buy" Rating for Cytosorbents Corporation (CTSO)
www.americanbankingnews.com - November 21 at 4:41 PM
Cytosorbents Corporation (CTSO) to Post Q1 2018 Earnings of ($0.10) Per Share, B. Riley ForecastsCytosorbents Corporation (CTSO) to Post Q1 2018 Earnings of ($0.10) Per Share, B. Riley Forecasts
www.americanbankingnews.com - November 13 at 6:00 AM
Cytosorbents Corporation (CTSO) Rating Reiterated by B. RileyCytosorbents Corporation (CTSO) Rating Reiterated by B. Riley
www.americanbankingnews.com - November 12 at 8:38 AM
CytoSorbents Recognized on Deloittes 2017 Technology Fast 500™ as One of the Fastest Growing Companies in ... - PR Newswire (press release)CytoSorbents Recognized on Deloitte's 2017 Technology Fast 500™ as One of the Fastest Growing Companies in ... - PR Newswire (press release)
www.prnewswire.com - November 11 at 10:46 AM

SEC Filings

Cytosorbents (NASDAQ:CTSO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cytosorbents (NASDAQ:CTSO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cytosorbents (NASDAQ CTSO) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.